FIGURE
Fig. 4
- ID
- ZDB-FIG-240729-122
- Publication
- Adekiya et al., 2024 - PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer
- Other Figures
- All Figure Page
- Back to All Figure Page
Fig. 4
Determination of reactive oxygen species (ROS) in unstimulated control (control - cells incubated with media only), control 2 (cells incubated with ROS-sensitive fluorescent indicator (H2DCFDA), pure brusatol (38.66 nM), pure docetaxel (60 nM), mixture of pure drugs (38.66 nM brusatol + 60 nM docetaxel), and nanoparticle formulations containing equivalents of the pure drug mixture at 2 h, and 24 h in LNCaP cells (left) and PC-3 cells (right). |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Biomed. Pharmacother.